Nisha Nanda, Ph.D.

Nisha Nanda is Group Vice President of Business Development, Cataylze360 at Lilly responsible for expanding Eli Lilly’s engagement and reach across the biotech ecosystem.

Prior to this role, Nisha was the Chief Development Officer and R&D Chief Operating Officer of Loxo Oncology at Lilly. Nisha joined Lilly in 2019 when the company acquired Loxo. While at Loxo, Nisha played an important role in the development and approval of cancer treatments (Vitrakvi, Retevmo and Jaypirca) and in driving the pre-clinical pipeline forward into later-stage development. Prior to Loxo, Nisha had been involved in the development of several other now-approved drugs: Kyprolis at Onyx; Synribo at ChemGenex, and Bevyxxa at Portola Pharmaceuticals. Nisha sits on the board of Morphic Therapeutics.

Following her undergraduate and doctorate in Biochemistry and Molecular Genetics from the UNSW and the Victor Chang Cardiac Research Institute, Sydney, Australia, Nisha has held multiple roles in research and development across medium to large multinational biotechnology companies, resulting in the approval of new treatment options for patients with cancer.